DOI QR코드

DOI QR Code

Role of the Mdm2 SNIP 309 Polymorphism in Gastric Mucosal Morphologic Patterns of Patients with Helicobacter pylori Associated Gastritis

  • Published : 2016.04.11

Abstract

Background: The tumor suppressor p53 is as a regulator of cell proliferation, apoptosis and many other biological processes as well as external and internal stress responses. Mdm2 SNIP309 is a negative regulator of 53. Therefore, this study aimed to determine the role of the Mdm2 SNIP 309 polymorphism in the gastric mucosal morphological patterns in patients with Helicobacter pylori associated gastritis. Materials and Methods: A prospective cross-sectional study was carried out from November 2014 through November 2015. Biopsy specimens were obtained from patients and infection was proven by positive histology. Gastric mucosa specimens were sent to the Molecular Genetics Unit, Institute of Medicine, Suranaree University of Technology where they were tested by molecular methods to detect the patterns of Mdm2 SNIP 309 polymorphism using the real-time PCR hybridization probe method. The results were analyzed and correlated with gastric mucosal morphological patterns by using C-NBI endoscopy. Results: A total of 300 infected patients were enrolled and gastric mucosa specimens were collected. In this study the percentage of Mdm2 SNIP 309 T/T homozygous and Mdm2 SNIP309 G/T heterozygous was 78% and 19 % respectively whereas Mdm2 SNIP309 G/G homozygous was 3%. Mdm2 SNIP 309 T/T homozygous and Mdm2 SNIP309 G/T heterozygosity correlated with type 1 to type 3 gastric mucosal morphological patterns (P<0.01) whereas Mdm2 SNIP309 G/G homozygous correlated with type 4 and type 5 (P<0.01). Conclusions: Our study finds the frequency of Mdm2 SNIP309 G/G in a Thai population is very low, and suggests that this can explain ae Thailand enigma. Types 1 to type 3 are the most common gastric mucosal morphological patterns according to the unique genetic polymorphism of MDM2 SNIP 309 in the Thai population.

Keywords

References

  1. Bond GL, Hu W, Levine AJ, et al (2005). MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets, 5, 3-8. https://doi.org/10.2174/1568009053332627
  2. Gono K, Obi T, Yamaguchi M, et al (2004). Appearance of enhanced tissue features in narrow-band endoscopic imaging. J Biomed Opt, 9, 568-77. https://doi.org/10.1117/1.1695563
  3. Gurova KV, Hill JE, Guo C, et al (2005). Small molecules that reactivate p53 in renal cell carcinoma reveals a nf-kappab-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci USA., 102, 17448-53. https://doi.org/10.1073/pnas.0508888102
  4. Haupt Y, Maya R, et al (1997). Mdm2 promotes the rapid degradation of p53. Nature, 387, 296-9. https://doi.org/10.1038/387296a0
  5. Honda R, Tanaka H, et al (1997). Oncoprotein MDM2 is an ubiquitin ligase E3 for tumor suppressor p53. FEBS Letters, 420, 25-7. https://doi.org/10.1016/S0014-5793(97)01480-4
  6. Kentaro S, Jan T, Ernst JK, et al (2015). Kyoto global consensus report on Helicobacter pylori gastritis. Gut, 64, 1353-67. https://doi.org/10.1136/gutjnl-2015-309252
  7. Komarova EA, Krivokrysenko V, Wang K, et al (2005). P53 is a suppressor of inflammatory response in mice. FASEB J, 19, 1030-2. https://doi.org/10.1096/fj.04-3213fje
  8. Kubbutat MH, Jones SN, et al (1997). Regulation of p53 stability by Mdm2. Nature, 387, 299-303. https://doi.org/10.1038/387299a0
  9. MF Dixon, RM Genta JH, Harley et al (1996). "Classification and grading of gastritis. The Updated Sydney system. Am J Surgical Pathol, 20, 1161-81.
  10. Momand J, Zambetti GP, et al (1992). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69, 1237- 45. https://doi.org/10.1016/0092-8674(92)90644-R
  11. Moradi MT, Salehi Z, Aminian K, et al (2014). Effects of p53 codon 72 and MDM2 SNP309 polymorphisms on gastric cancer risk among the Iranian population. Asian Pac J Cancer Prev, 15, 7413-7. https://doi.org/10.7314/APJCP.2014.15.17.7413
  12. O'Prey J, Crighton D, Martin AG, et al (2010). P53-mediated induction of noxa and p53aip1 requires nfkappab. Cell Cycle, 9, 947-52. https://doi.org/10.4161/cc.9.5.10872
  13. Picksley SM, Lane DP et al (1993).The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays, 15, 689-90. https://doi.org/10.1002/bies.950151008
  14. Taweesak T, Soraya K, Natthawut K, et al (2015). Correlation between gastric mucosal morphologic patterns and histopathological severity of helicobacter pylori associated gastritis using conventional narrow band imaging gastroscopy. Bio Med Res Int, 7, 42-8.
  15. Tergaonkar V, Pando M, Vafa O, et al (2002). P53 stabilization is decreased upon nf kappa b activation: A role for nfkappab in acquisition of resistance to chemotherapy. Cancer Cell, 1, 493-503. https://doi.org/10.1016/S1535-6108(02)00068-5
  16. Wang X, Yang J, Ho B, et al (2009). Interaction of Helicobacter pylori with genetic variants in the MDM2 promoter is associated with gastric cancer susceptibility in Chinese patients. Helicobacter, 14, 114-9.
  17. Yagi K, Nakamura A, Sekine A, et al (2002). Comparison between magnifying endoscopy and histological, culture and urease test findings from the gastric mucosa of the corpus. Endoscopy, 34, 376-81. https://doi.org/10.1055/s-2002-25281

Cited by

  1. Interaction with AEG-1 and MDM2 is associated with glioma development and progression and correlates with poor prognosis vol.18, pp.2, 2019, https://doi.org/10.1080/15384101.2018.1557489
  2. Genetic polymorphisms in TLR1, TLR2, TLR4, and TLR10 of Helicobacter pylori-associated gastritis in Thai population vol.28, pp.2, 2019, https://doi.org/10.1097/CEJ.0000000000000434